Related Experiment Videos
Low-dose aprotinin in cardiac operations
R Haddad1, C Kesrouani, W Nasr
1Department of Surgery, American University of Beirut-Medical Center, Beirut, Lebanon. mrsmith@dm.net.lb
Insights
Low-dose aprotinin significantly reduces bleeding and transfusion needs in cardiac surgery patients taking aspirin. This finding is crucial for improving patient outcomes during heart operations.
Area of Science:
- Cardiology
- Anesthesiology
- Hematology
Background:
- Aspirin is commonly prescribed for heart disease patients.
- Aspirin use increases bleeding risk during cardiac surgery due to platelet dysfunction.
Purpose of the Study:
- To evaluate the effectiveness of low-dose aprotinin in reducing blood loss and transfusion requirements.
- To assess aprotinin's efficacy in patients undergoing cardiac surgery who are also taking aspirin.
Main Methods:
- Retrospective analysis of 82 open-heart surgery patients.
- Patients categorized into three groups: no aspirin/aprotinin, aspirin + aprotinin, and aspirin only.
- Primary outcomes measured: total blood loss and transfusion volume.
Main Results:
- Aprotinin group showed significantly lower total blood loss (359 ml) compared to control groups (527 ml and 628 ml).
- Bleeding rates were significantly reduced in the aprotinin group (17.2 ml/hr).
- Transfusion volumes and prevalence were lower in patients receiving aprotinin.
Conclusions:
- Low-dose aprotinin is effective in minimizing blood loss during cardiac surgery.
- Aprotinin reduces the need for blood transfusions in aspirin-treated patients undergoing heart operations.
Background:
Patients with heart disease are frequently maintained on a regimen of aspirin. During cardiac surgery aspirin-induced platelet dysfunction increases the risk of bleeding.
Methods:
The files of 82 patients who had undergone open-heart surgery were selected to study the efficacy of the low-dose (2 million KIU) aprotinin regimen in decreasing blood loss and transfusion requirements for patients receiving aspirin. Patients were divided into three groups: Group 1, includes those who received neither aspirin nor aprotinin (n = 41), Group 2, received both aspirin and aprotinin (n = 27) and Group 3, did not receive aprotinin despite aspirin intake (n = 14). Primary outcome measures in this study were total volume of blood loss (postoperative chest tube drainage) and volume of transfusions during hospitalization.
Results:
Patients treated with aprotinin (Group 2) had significantly lower total blood loss (359 ml versus 527 ml and 628 ml in Group 1 and Group 3, p < 0.05), rates of bleeding (17.2 ml/hr versus 25.7 and 30.4 ml/hr in groups 1 and 3 respectively). A significant difference was also found when comparing the volume of blood transfusions (224.4 ml versus 262.4 and 537.5 ml) and prevalence of transfusion (33.3% versus 36.6% and 64.3%).
Conclusion:
Low-dose aprotinin significantly reduces blood loss and blood transfusions in patients receiving aspirin who undergo cardiac operations.